Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon

NCT02591225 ·Status: UNKNOWN ·Phase: PHASE4

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

NCT02067182 ·Status: COMPLETED ·Phase: PHASE4

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

NCT02022020 ·Status: COMPLETED

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

NCT02061748 ·Status: COMPLETED

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

NCT02240667 ·Status: COMPLETED

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

NCT01184989 ·Status: COMPLETED ·Phase: PHASE4

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

NCT03254134 ·Status: COMPLETED

Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery

NCT00846807 ·Status: COMPLETED

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

NCT02666157 ·Status: UNKNOWN ·Phase: PHASE4

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

NCT00742859 ·Status: COMPLETED ·Phase: PHASE2

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

NCT01606995 ·Status: COMPLETED

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

NCT00818753 ·Status: COMPLETED ·Phase: PHASE2

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

NCT00847301 ·Status: COMPLETED

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150 ·Status: UNKNOWN

Patient Convenience Study (RE-SONANCE)

NCT02684981 ·Status: COMPLETED

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

NCT03742336 ·Status: COMPLETED ·Phase: PHASE1

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

NCT00262600 ·Status: COMPLETED ·Phase: PHASE3

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

NCT02714855 ·Status: COMPLETED

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

NCT02072434 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

NCT00291330 ·Status: COMPLETED ·Phase: PHASE3

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

NCT02283294 ·Status: COMPLETED ·Phase: PHASE3

Patient Convenience Study

NCT02597920 ·Status: COMPLETED

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

NCT02864758 ·Status: COMPLETED

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

NCT02596555 ·Status: TERMINATED ·Phase: PHASE4